Isabel Caraballo

Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism

Emilio Fernández‐Espejo, Isabel Caraballo, Fernando Rodrı́guez de Fonseca et al. · Neurobiology of Disease · 2005 · 102 citations · Full text

Medicine, Neuroscience, Pharmacology +12

Experimental Parkinsonism Alters Anandamide Precursor Synthesis, and Functional Deficits are Improved by AM404: A Modulator of Endocannabinoid Function

Emilio Fernández‐Espejo, Isabel Caraballo, Fernando Rodrı́guez de Fonseca et al. · Neuropsychopharmacology · 2004 · 70 citations

Life Sciences, Neuroscience, Pharmacology +14

Functional Regeneration in a Rat Parkinson's Model after Intrastriatal Grafts of Glial Cell Line-Derived Neurotrophic Factor and Transforming Growth Factor β₁-Expressing Extra-Adrenal Chromaffin Cells of the Zuckerkandl's Organ

Emilio Fernández‐Espejo, M. C. Gonzalez-Albo, Joao-Paulo Moraes et al. · Journal of Neuroscience · 2001 · 45 citations · Full text

Life Sciences, Neurobiology, Neuroscience +17

Effects on turning of microinjections into basal ganglia of D1 and D2 dopamine receptors agonists and the cannabinoid CB1 antagonist SR141716A in a rat Parkinson's model

Fadwa El Banoua, Isabel Caraballo, Juan A. Flores et al. · Neurobiology of Disease · 2004 · 43 citations · Full text

Life Sciences, Neuroscience, Pharmacology +17